Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BEBT-908 plus BEBT-209 in HR-positive/HER2-negative advanced breast cancer after progression on CDK4/6 inhibitor therapy
CTR20213267Phase 2Active
- Sponsor
- BeBetter Med
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifupinostat and bebt-209 in breast cancer (5 arms), sponsored by BeBetter Med. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicity and 1 more. Started Mar 2022; status: active.
02
Drugs
ifupinostatbebt-209
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20213267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213267.